Yong‐Su Zhen

2.9k total citations · 1 hit paper
154 papers, 2.3k citations indexed

About

Yong‐Su Zhen is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Yong‐Su Zhen has authored 154 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Molecular Biology, 61 papers in Oncology and 36 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Yong‐Su Zhen's work include Cancer therapeutics and mechanisms (33 papers), Monoclonal and Polyclonal Antibodies Research (33 papers) and Chemical Synthesis and Analysis (22 papers). Yong‐Su Zhen is often cited by papers focused on Cancer therapeutics and mechanisms (33 papers), Monoclonal and Polyclonal Antibodies Research (33 papers) and Chemical Synthesis and Analysis (22 papers). Yong‐Su Zhen collaborates with scholars based in China, United States and United Kingdom. Yong‐Su Zhen's co-authors include Shenghua Zhang, Rong‐Guang Shao, Xiujun Liu, George Weber, Liang Li, Shiming He, Jian Xu, I. Goldberg, Shousong Cao and Yajun Lin and has published in prestigious journals such as Journal of the American Chemical Society, PLoS ONE and Biochemistry.

In The Last Decade

Yong‐Su Zhen

150 papers receiving 2.3k citations

Hit Papers

Advances and challenges in the treatment of esophageal ca... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Advances and challenges in the treatment of esophageal cancer
    2021 174 citations Shiming He, Jian Xu et al. Acta Pharmaceutica Sinica B profile →

Peers

Yong‐Su Zhen
John J. Pink United States
Susan L. Holbeck United States
Jinliang Yang China
Anna Long United Kingdom
Steven D. Shnyder United Kingdom
Siro Simizu Japan
Robert J. Hickey United States
Michelandrea De Cesare Italy
Swee Y. Sharp United Kingdom
Anne M. Hassell United States
John J. Pink United States
Yong‐Su Zhen
Citations per year, relative to Yong‐Su Zhen Yong‐Su Zhen (= 1×) peers John J. Pink

Countries citing papers authored by Yong‐Su Zhen

Since Specialization
Citations

This map shows the geographic impact of Yong‐Su Zhen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yong‐Su Zhen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yong‐Su Zhen more than expected).

Fields of papers citing papers by Yong‐Su Zhen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yong‐Su Zhen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yong‐Su Zhen. The network helps show where Yong‐Su Zhen may publish in the future.

Co-authorship network of co-authors of Yong‐Su Zhen

This figure shows the co-authorship network connecting the top 25 collaborators of Yong‐Su Zhen. A scholar is included among the top collaborators of Yong‐Su Zhen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yong‐Su Zhen. Yong‐Su Zhen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yi, et al.. (2024). The triple combination DBDx alleviates cytokine storm and related lung injury. International Immunopharmacology. 143(Pt 2). 113431–113431.
2.
Zhou, Dandan, et al.. (2024). A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers. npj Precision Oncology. 8(1). 94–94. 13 indexed citations
3.
Sun, Liping, Dandan Zhou, Xiaofan Wu, et al.. (2023). hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. Journal of Medicinal Chemistry. 66(21). 14700–14715. 6 indexed citations
4.
Hong, Hanyu, Yujing Li, Junyi Zhang, et al.. (2023). An albumin-binding lidamycin prodrug for efficient targeted cancer therapy. Journal of Drug Delivery Science and Technology. 91. 105213–105213. 1 indexed citations
5.
He, Shiming, et al.. (2021). Advances and challenges in the treatment of esophageal cancer. Acta Pharmaceutica Sinica B. 11(11). 3379–3392. 174 indexed citations breakdown →
6.
Tao, Hongyu, et al.. (2021). The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy. International Journal of Biological Macromolecules. 187. 24–34. 95 indexed citations
7.
Zheng, Yanbo, Jianhua Gong, & Yong‐Su Zhen. (2020). Focal adhesion kinase is activated by microtubule‐depolymerizing agents and regulates membrane blebbing in human endothelial cells. Journal of Cellular and Molecular Medicine. 24(13). 7228–7238. 6 indexed citations
8.
Wang, Rong, Liang Li, Aijun Duan, et al.. (2019). Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. Cancer Letters. 448. 84–93. 12 indexed citations
9.
Wang, Yangyang, Liang Li, Yi Li, et al.. (2018). A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer. Molecular Pharmaceutics. 15(6). 2403–2412. 25 indexed citations
10.
Liu, Wenjuan, Xiujun Liu, Jian Xu, et al.. (2018). EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis. Acta Pharmacologica Sinica. 39(11). 1777–1786. 22 indexed citations
11.
Zhen, Yong‐Zhan, et al.. (2016). Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice. Journal of Cancer Research and Therapeutics. 12(1). 182–182. 3 indexed citations
12.
Zheng, Yanbo, et al.. (2016). A CD13‐targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis. Molecular Carcinogenesis. 56(5). 1395–1404. 37 indexed citations
13.
Xu, Jian, Xiujun Liu, Liang Li, et al.. (2015). An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget. 6(28). 26322–26334. 20 indexed citations
14.
Li, Xingqi, Shenghua Zhang, Hong Liu, et al.. (2014). Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin. Cancer Biology & Therapy. 15(4). 398–408. 9 indexed citations
15.
Chen, Yi, Dongke Yu, Caixia Zhang, et al.. (2013). Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3β/β‐catenin pathway. Molecular Carcinogenesis. 54(1). 1–8. 19 indexed citations
16.
Guo, Xiaofang, Xiaofei Zhu, Yue Shang, Shenghua Zhang, & Yong‐Su Zhen. (2010). A Bispecific Enediyne-Energized Fusion Protein Containing Ligand-Based and Antibody-Based Oligopeptides against Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Shows Potent Antitumor Activity. Clinical Cancer Research. 16(7). 2085–2094. 38 indexed citations
17.
Wang, Xiangbin, et al.. (2008). A novel bivalent single‐chain variable fragment (scFV) inhibits the action of tumour necrosis factor α. Biotechnology and Applied Biochemistry. 50(4). 173–179. 9 indexed citations
18.
Xu, Feng, Shenghua Zhang, Rong‐Guang Shao, & Yong‐Su Zhen. (2005). Anticancer activity of sodium caffeate and its mechanism1. Acta Pharmacologica Sinica. 26(10). 1248–1252. 14 indexed citations
19.
Zhen, Yong‐Su, et al.. (1994). Antitumor activity of immunoconjugates composed of boanmycin and monoclonal antibody.. PubMed. 9(2). 75–80. 3 indexed citations
20.
Zhen, Yong‐Su, et al.. (1987). [Antitumor activity of bleomycin A6 against human liver cancer in cell culture and in nude mice].. PubMed. 22(12). 881–5. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John J. Pink Breakdown of academic impact, for papers by Susan L. Holbeck Breakdown of academic impact, for papers by Jinliang Yang Breakdown of academic impact, for papers by Anna Long Breakdown of academic impact, for papers by Steven D. Shnyder Breakdown of academic impact, for papers by Siro Simizu Breakdown of academic impact, for papers by Robert J. Hickey Breakdown of academic impact, for papers by Michelandrea De Cesare Breakdown of academic impact, for papers by Swee Y. Sharp Breakdown of academic impact, for papers by Anne M. Hassell
Rankless by CCL
2026